Atlas Trials

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

Clinical trial NCT03012100 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03012100
Sponsor
Academic and Community Cancer Research United
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Bilateral Breast CarcinomaBreast Inflammatory CarcinomaStage IB Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7Stage IIB Breast Cancer AJCC v6 and v7Stage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Triple-Negative Breast CarcinomaUnilateral Breast Carcinoma
Start date
2017-03-31
Primary completion
2025-02-28
Enrollment
280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.